Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 Nov 1;6(11):e2340608.
doi: 10.1001/jamanetworkopen.2023.40608.

Streptococcus salivarius Probiotics to Prevent Acute Otitis Media in Children: A Randomized Clinical Trial

Suvi Sarlin  1   2 , Ulla Koskela  1   2 , Minna Honkila  1   2 , Paula A Tähtinen  3 , Tytti Pokka  2   4 , Marjo Renko  5 , Terhi Tapiainen  1   2
Affiliations
Randomized Controlled Trial

Streptococcus salivarius Probiotics to Prevent Acute Otitis Media in Children: A Randomized Clinical Trial

Suvi Sarlin et al. JAMA Netw Open. .

Erratum in

  • Errors in Table.
    [No authors listed] [No authors listed] JAMA Netw Open. 2023 Dec 1;6(12):e2352223. doi: 10.1001/jamanetworkopen.2023.52223. JAMA Netw Open. 2023. PMID: 38150259 Free PMC article. No abstract available.

Abstract

Importance: New approaches for the prevention of acute otitis media (AOM), the most common reason for antibiotic use in children, are needed.

Objective: To assess the efficacy of the Streptococcus salivarius K12 oral probiotics in the primary prevention of AOM.

Design, setting, and participants: This double-blind, randomized placebo-controlled clinical trial was conducted from August 1, 2020, to May 31, 2021, at 50 day care centers in the Oulu region of Finland. A total of 827 children aged 1 to 6 years attending day care were included. The exclusion criteria consisted of ongoing antimicrobial prophylaxis or immunodeficiency. The follow-up time was 6 months and was completed on May 31, 2021. Data were analyzed from October 24, 2022, to September 16, 2023, based on intention to treat.

Intervention: Eligible participants were randomly allocated to receive 1 daily dose of a S salivarius K12 product or placebo every evening for 6 months. A daily dose was defined as 1 sachet of soluble oral powder for children younger than 3 years or 1 chewable tablet for children 3 years or older containing 1 × 109 colony-forming units of S salivarius K12.

Main outcomes and measures: The primary outcome was the proportion of children with at least 1 episode of AOM requiring antimicrobial therapy within 6 months of randomization. All physician visits and purchases of antimicrobial drugs were retrieved from the electronic national medical record and prescription register. The primary outcome was met if the legal guardian had purchased an antimicrobial prescription for AOM.

Results: A total of 827 children with a mean (SD) age of 4.1 (1.6) years (433 boys [52.4%]) were randomized to S salivarius K12 oral products (n = 413) or placebo (n = 414). Thirty-four children (8.2%) in the S salivarius group and 24 children (5.8%) in the placebo group experienced at least 1 episode of AOM requiring antimicrobial therapy during the 6-month follow-up period (relative risk, 1.42 [95% CI, 0.86-2.34]; proportion difference, -2.44% [95% CI, -5.94% to 1.09%]; P = .17). Time to first AOM episode did not differ between the groups (174 [95% CI, 171-177] days in the S salivarius group vs 176 [95% CI, 173-179] days in the placebo group; P = .18).

Conclusions and relevance: In this randomized placebo-controlled clinical trial, the daily use of the S salivarius K12 products for 6 months did not reduce the occurrence of AOM. New approaches for primary prevention of AOM among children are needed.

Trial registration: ClinicalTrialsRegister.eu Identifier: 2020-001076-14.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Figures

Figure 1.
Figure 1.. Study Flow Diagram
Figure 2.
Figure 2.. Time to First Episode of Acute Otitis Media (AOM) Requiring Antimicrobial Therapy During the Intervention
The P value was obtained via a log-rank test for difference between groups.
See this image and copyright information in PMC

References

    1. Vaz LE, Kleinman KP, Raebel MA, et al. . Recent trends in outpatient antibiotic use in children. Pediatrics. 2014;133(3):375-385. doi:10.1542/peds.2013-2903 - DOI - PMC - PubMed
    1. Jokinen J, Palmu AA, Kilpi T. Acute otitis media replacement and recurrence in the Finnish Otitis Media Vaccine trial. Clin Infect Dis. 2012;55(12):1673-1676. doi:10.1093/cid/cis799 - DOI - PubMed
    1. Fireman B, Black SB, Shinefield HR, Lee J, Lewis E, Ray P. Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr Infect Dis J. 2003;22(1):10-16. doi:10.1097/00006454-200301000-00006 - DOI - PubMed
    1. Karppinen S, Toivonen L, Schuez-Havupalo L, et al. . Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against all respiratory tract infections in children under two years of age. Vaccine. 2019;37(22):2935-2941. doi:10.1016/j.vaccine.2019.04.026 - DOI - PubMed
    1. Vesikari T, Forsten A, Seppä I, et al. . Effectiveness of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D–conjugated vaccine (PHiD-CV) against carriage and acute otitis media—a double-blind randomized clinical trial in Finland. J Pediatric Infect Dis Soc. 2016;5(3):237-248. doi:10.1093/jpids/piw010 - DOI - PMC - PubMed

Publication types

Substances